Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury

Stem Cells

Volumn 33, Issue 2, 2015, Pages 456-467

  Wang, Zhe ^a   Wang, Yu ^a,b   Wang, Zhiyong ^c   Gutkind, J Silvio ^c   Wang, Zhongliang ^a,d   Wang, Fu ^a,d   Lu, Jie ^a   Niu, Gang ^a   Teng, Gaojun ^b   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^d XIDIAN UNIVERSITY   (China)

Author keywords

Angiogenesis; CXC chemokine receptor 4; Imaging; Mesenchymal stem cell; Neuron; Traumatic brain injury

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BRAIN BLOOD FLOW; CELL DIFFERENTIATION; CELL ENGINEERING; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MOUSE; NEUROPROTECTION; NONHUMAN; PARACRINE SIGNALING; POSITIVE FEEDBACK; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TRAUMATIC BRAIN INJURY; TROPISM; ALLOGRAFT; ANIMAL; BIOSYNTHESIS; BRAIN INJURIES; CONVALESCENCE; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ALLOGRAFTS; ANIMALS; BRAIN INJURIES; CELL ENGINEERING; CHEMOKINE CXCL12; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; PARACRINE COMMUNICATION; RECEPTORS, CXCR4; RECOVERY OF FUNCTION;

EID: 84921685348     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1878     Document Type: Article

References (52)

1. Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013; 19: 35-42.
2. glesias-Bartolome R, Patel V, Cotrim A, et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 2012; 11: 401-414.
3. Nauta AJ, Fibbe WE,. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
4. Baraniak PR, McDevitt TC,. Stem cell paracrine actions and tissue regeneration. Regen Med 2010; 5: 121-143.
5. Karp JM, Leng Teo GS,. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009; 4: 206-216.
6. Harting MT, Jimenez F, Xue H, et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009; 110: 1189-1197.
7. Zhang ZX, Guan LX, Zhang K, et al. A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008; 10: 134-139.
8. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14: 181-187.
9. Shen LH, Li Y, Chen J, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007; 27: 6-13.
10. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1α/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 2004; 101: 18117-18122.
11. Nakano-Doi A, Nakagomi T, Fujikawa M, et al. Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells 2010; 28: 1292-1302.
12. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-848.
13. Brenner S, Whiting-Theobald N, Kawai T, et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells 2004; 22: 1128-1133.
14. Tsai LK, Wang Z, Munasinghe J, et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 2011; 42: 2932-2939.
15. Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7: e34608.
16. Khoo CP, Micklem K, Watt SM,. A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. Tissue Eng Part C Methods 2011; 17: 895-906.
17. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201.
18. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
19. Wang Z, Chui WK, Ho PC,. Integrin targeted drug and gene delivery. Expert Opin Drug Deliv 2010; 7: 159-171.
20. Wang Z, Chui WK, Ho PC,. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm Res 2011; 28: 585-596.
21. Lee RH, Yoon N, Reneau JC, et al. Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell Stem Cell 2012; 11: 825-835.
22. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
23. Byrne AM, Bouchier-Hayes DJ, Harmey JH,. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9: 777-794.
24. Wang Z, Ho PC,. Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small 2010; 6: 2576-2583.
25. Wang Z, Ho PC,. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 2010; 31: 7115-7123.
26. Huang EJ, Reichardt LF,. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736.
27. Chopp M, Li Y,. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92-100.
28. Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-Similarities to astrocyte grafts. Proc Natl Acad Sci USA 1998; 95: 3908-3913.
29. Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA 2004; 101: 11839-11844.
30. Yu X, Chen D, Zhang Y, et al. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J Neurol Sci 2012; 316: 141-149.
31. Ranganath SH, Levy O, Inamdar MS, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012; 10: 244-258.
32. Lee RH, Hsu SC, Munoz J, et al. A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood 2006; 107: 2153-2161.
33. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571-579.
34. Franke TF, Kaplan DR, Cantley LC,. PI3K: Downstream AKTion blocks apoptosis. Cell 1997; 88: 435-437.
35. Gnecchi M, Zhang Z, Ni A, et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219.
36. Menge T, Zhao Y, Zhao J, et al. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med 2012; 4: 161ra150.
37. Wilkins A, Kemp K, Ginty M, et al. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009; 3: 63-70.
38. Islam O, Loo TX, Heese K,. Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res 2009; 6: 42-53.
39. Kortesidis A, Zannettino A, Isenmann S, et al. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005; 105: 3793-3801.
40. Carlson KB, Singh P, Feaster MM, et al. Mesenchymal stem cells facilitate axon sorting, myelination, and functional recovery in paralyzed mice deficient in Schwann cell-derived laminin. Glia 2011; 59: 267-277.
41. Wislet-Gendebien S, Hans G, Leprince P, et al. Plasticity of cultured mesenchymal stem cells: Switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005; 23: 392-402.
42. Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555.
43. Liu Y, Wang L, Kikuiri T, et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med 2011; 17: 1594-1601.
44. Bai L, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 2012; 15: 862-870.
45. Levy O, Zhao W, Mortensen LJ, et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013; 122: e23-32.
46. Sarkar D, Spencer JA, Phillips JA, et al. Engineered cell homing. Blood 2011; 118: e184-e191.
47. Sage EK, Kolluri KK, McNulty K, et al. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax 2014; 69: 638-647.
48. Wang F, Wang Z, Hida N, et al. A cyclic HSV1-TK reporter for real-time PET imaging of apoptosis. Proc Natl Acad Sci USA 2014; 111: 5165-5170.
49. Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010; 16: 1035-1041.
50. Wang Z, Yue X, Wang Y, et al. A symmetrical fluorous dendron-cyanine dye-conjugated bimodal nanoprobe for quantitative F MRI and NIR fluorescence bioimaging. Adv Healthc Mater 2014; 3: 1326-1333.
51. Wang Z, Zhang X, Huang P, et al. Dual-factor triggered fluorogenic nanoprobe for ultrahigh contrast and subdiffraction fluorescence imaging. Biomaterials 2013; 34: 6194-6201.
52. Wang Z, Niu G, Chen X,. Polymeric materials for theranostic applications. Pharm Res 2014; 31: 1358-1376.